Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccine co-administration with COVID-19 vaccines
ACTRN12621001063808Phase 4Suspended
- Sponsor
- The Children's Hospital at Westmead
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ARCT-2138, ChAdOx1 nCoV-19, tozinameran, elasomeran and NVX-CoV2373 in influenza and coronavirus disease 2019 (COVID-19), sponsored by The Children's Hospital at Westmead. Started Nov 2021; status: suspended.
02
Drugs
ARCT-2138ChAdOx1 nCoV-19tozinameranelasomeranNVX-CoV2373
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621001063808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001063808.